In this interview, we speak with Dr. Robert Ferris about the results from the CheckMate-141 study, which investigated the efficacy of nivolumab in head and neck cancer.
Patients with metastatic Merkel cell carcinoma treated with pembrolizumab (Keytruda, Merck) as a first-line therapy had durable responses in a phase II clinical trial.
NEW ORLEANS – A new type of antibody-drug conjugate (ADC) platform may pave the way to help patients with ovarian cancer and non-small cell lung cancer.
Three commercial tests that measure levels of PD-L1 on tumors showed similar results on non-small cell lung cancer (NSCLC) tumor samples.
Immunotherapy treatment with nivolumab significantly improved survival among patients with recurrent or metastatic head and neck squamous cell carcinoma.
Results of a trial involving a CD4-based immunotherapy has shown activity in patients with metastatic solid tumors, according to phase I data presented at the AACR Annual Meeting.
More than one-third of patients with advanced melanoma were still alive 5 years after starting treatment with the anti-PD-1 immunotherapy nivolumab, according to long-term phase I data.
New data indicates that entrectinib has clinical activity in patients with a variety of cancers with gene alterations in NTRK1/2/3, ROS1, or ALK who had never been treated with targeted agents.